Pharmacogenomics of depression

Advances in Biological Psychiatry

Volumn 25, Issue , 2010, Pages 58-74

  Serretti, Alessandro ^a   Drago, Antonio ^a   Spina, Edoardo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870284629     PISSN: 03787354     EISSN: 16622774     Source Type: Book Series    
DOI: 10.1159/000317299     Document Type: Review

References (24)

1. Murray CJ, Lopez AD: Evidence-based health policy: Lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743.
2. Stahl SM: Stahl's Essential Psychopharmacology, ed 3. Cambridge, Cambridge University Press, 2008.
3. Moncrieff J, Kirsch I: Efficacy of antidepressants in adults. BMJ 2005; 331: 551-557.
4. Nierenberg AA: Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am 2003; 26: 345-352.
5. Perlis RH: Pharmacogenetic studies of antidepressant response: How far from the clinic? Psychiatr Clin North Am 2007; 30: 125-138.
6. Horstmann S, Binder EB: Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009; 124: 57-73.
7. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J: Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
8. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphism on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
9. Spina E, Santoro V, D'Arrigo C: Clinically relevant pharmacokinetic drug interactions with secondgeneration antidepressants: An update. Clin Ther 2008; 30: 1206-1227.
10. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-122.
11. Bertilsson L: Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: Clinical and interethnic aspects. Clin Pharmacol Ther 2007; 82: 606-609.
12. Wedlund PJ, de Leon J: Cytochrome P4502D6 and antidepressant toxicity and response: What is the evidence? Clin Pharmacol Ther 2004; 75: 373-375.
13. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation specific dosages. Acta Psychiatr Scand 2001; 104: 173-192.
14. de Leon J: The crucial role of therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotype in subjects taking drugs metabolized by CYP2D6 and CYP2C19. J Clin Psychopharmacol 2007; 27: 241-245.
15. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987; 77: 142-144.
16. Linnet K, Ejsing TB: A review on the impact of Pglycoprotein on the penetration of drugs into the brain: Focus on psychotropic drugs. Eur Neuropsychopharmacol 2008; 18: 157-169.
17. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191-196.
18. Laika B, Leucht S, Steimer W: ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): Lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 2006; 52: 893-895.
19. Fukui N, Suzuki Y, Sawamura K, Sugai T, Watanabe J, Inoue Y, Someya T: Dose-dependent effects of the 3435 C 1 T genotype of ABCB1 gene on the steadystate plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 2007; 29: 185-189.
20. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-209.
21. Zill P, Buttner A, Eisenmenger W, Moller H, Ackenheil M, Bondy B: Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study. J Psychiatr Res 2007; 41: 168-173.
22. Sakowski SA, Geddes TJ, Thomas DM, Levi E, Hatfield JS, Kuhn DM: Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res 2006; 1085: 11-18.
23. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M: Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry 2004; 56: 581-586.
24. Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, Enoch MA, Virkkunen M, Goldman D: Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry 2005; 62: 1109-1118.